<DOC>
	<DOCNO>NCT00823836</DOCNO>
	<brief_summary>To investigate efficacy safety ropinirole PR/XR tablet ropinirole immediate release ( IR ) tablet advance Parkinson 's disease conjunction L-dopa double-blind , parallel group comparison study .</brief_summary>
	<brief_title>Clinical Evaluation Ropinirole Prolonged Release/Extended Release ( PR/XR ) Tablet Adjunctive Therapy L-dopa Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Inclusion criterion start screen Patients diagnose advanced Parkinson 's disease ( PD ) severity modify Hoehn &amp; Yahr criterion Stages IIIV . Subjects receive stable dose Ldopa least 4 week prior screen phase demonstrate lack control Ldopa therapy follow circumstance . Wearingoff phenomenon . Onoff fluctuation . Delayedon/No phenomenon . Not adequately control Ldopa QTc &lt; 450 millisecond ( msec ) &lt; 480msec patient Bundle Branch Block value base either single ECG value triplicate electrocardiogram ( ECG ) average QTc value obtain brief recording period . Age:20 year older ( time inform write consent ) Informed consent : Patients able give inform write consent person . ( i.e . patient capable give informed write consent one 's ) Sex : either sex . Female childbearing potential eligible inclusion study . However negative pregnancy test screen visit , agree pregnancy test time point determine study assessment procedure practice one follow method contraception screen visit end followup examination . Abstinence . Injectable progestogen . Implants levonorgestrel . Estrogenic vaginal ring . Percutaneous contraceptive patch . Intrauterine device ( IUD ) intrauterine system ( IUS ) meet SOP effectiveness criterion state product label . Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject . Double barrier method : condom occlusive cap ( diaphragm cervical / vault cap ) plus spermicidal agent ( foam /gel / film / cream / suppository ) Both inpatient outpatient status . Inclusion Criteria start noninferiority verification phase Patients whose Unified Parkinson 's Disease Rating Scale ( UPDRS ) PartIII total ( ) score 10 point week 0 . Late stage advance subject demonstrate incapacitate peak dose biphasic dyskinesia stable dose Ldopa . Patients present serious physical sign symptom PD ( e.g . cardiac/hepatic/renal disorder haematopoietic disorder ) . The severity refers Grade 3 accord `` Classification Severity Adverse Experiences ( Pharmaceutical affair bureau/Safety division ( PAB/SD ) Notification No . 80 , date 29 June 1992 ) . Patients symptomatic postural hypotension . ( e.g . dizziness syncope ) . Patients current history drug abuse alcoholism . Patients receive surgical treatment PD past ( e.g . pallidectomy , deep brain stimulation ) . Female patient pregnant lactating , may pregnant , plan pregnancy study within 30 day last dose study drug . Patients chronic hepatitis typeB and/or type C positive hepatitis B surface antigen ( HBsAg ) and/or hepatitis C antibody . Patients history drug allergy ropinirole hydrochloride ( HCl ) . Patients current history cancer malignant tumor . Others investigator ( subinvestigator ) considers ineligible study . Exclusion criterion start noninferiority verification phase Patients severe dementia ( e.g . score 3 4 UPDRS item 1 ( Intellectual Impairment ) ) Patients current history major psychosis ( e.g . schizophrenia psychotic depression ) core 3 4 UPDRS item 2 ( think disorder ) item 3 ( depression ) . Patients used dopamine agonist within 4 week prior noninferiority verification phase Patients treat follow drug 4 week earlier start noninferiority verification phase , whose treatment regimen drug change . Anticholinergic agent : trihexyphenidyl hydrochloride ( e.g . Artane® ) , piroheptine hydrochloride ( Trimol® ) , mazaticol hydrochloride ( Pentona® ) , metixene hydrochloride ( Cholinfall® ) , biperiden hydrochloride ( Akineton® ) , profenamine ( Parkin® ) , amantadine hydrochloride ( e.g . Symmetrel® ) , droxidopa ( Dops® ) , citicoline ( e.g . Nicholin® ) , selegiline hydrochloride ( FP® ) , entacapone , ( comutan® ) zonisamide , Estrogens : e.g . estriol ( e.g . Estriel® ) , CYP1A2 inhibitor : Ciprofloxacin HCl ( e.g . Ciproxan® , enoxacin fluvoxamine ) . Patients treat investigational drug within 12 week prior treatment phase .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Ropinirole , advance Parkinson 's disease , L-dopa adjunctive therapy</keyword>
</DOC>